Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
$11.33
+3.2%
$8.36
$3.76
$46.80
$67.54M2.7774,991 shs102,966 shs
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$5.01
-0.6%
$4.65
$3.61
$11.09
$59.41M1.5283,417 shs57,943 shs
Dyadic International Inc. stock logo
DYAI
Dyadic International
$0.93
+2.9%
$0.95
$0.71
$2.20
$32.74M0.89143,479 shs186,440 shs
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
$0.94
-3.0%
$0.89
$0.63
$1.78
$35.94M0.349,375 shs4,756 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
+3.19%+28.02%+29.34%+97.39%-13.51%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
-0.60%+7.51%-1.76%+1.83%-48.40%
Dyadic International Inc. stock logo
DYAI
Dyadic International
+2.91%+14.94%-16.13%-10.05%-37.52%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-3.04%+1.84%+2.17%-5.53%-15.32%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
4.4888 of 5 stars
3.54.00.04.82.91.70.6
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
4.0131 of 5 stars
3.51.00.04.62.71.70.6
Dyadic International Inc. stock logo
DYAI
Dyadic International
3.4297 of 5 stars
3.55.00.00.02.73.30.0
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
3.1458 of 5 stars
3.55.00.00.03.31.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
3.00
Buy$50.00341.31% Upside
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
3.00
Buy$47.00838.12% Upside
Dyadic International Inc. stock logo
DYAI
Dyadic International
3.00
Buy$6.00544.47% Upside
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
3.00
Buy$16.001,602.13% Upside

Current Analyst Ratings Breakdown

Latest DTIL, ALGS, ESLA, and DYAI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$50.00
8/12/2025
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
5/29/2025
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
$3.94M17.69N/AN/A$16.56 per share0.68
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$68.70M0.86N/AN/A$2.89 per share1.73
Dyadic International Inc. stock logo
DYAI
Dyadic International
$3.49M9.65N/AN/A($0.01) per share-93.10
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/AN/AN/AN/A($0.16) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
-$131.21M-$19.79N/AN/AN/A-2,337.24%-22.41%-12.09%11/5/2025 (Estimated)
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$7.17M-$8.81N/AN/AN/A-6,205.79%-176.47%-69.05%11/3/2025 (Estimated)
Dyadic International Inc. stock logo
DYAI
Dyadic International
-$5.81M-$0.19N/AN/AN/A-134.84%-355.39%-60.66%11/11/2025 (Estimated)
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/A-$0.26N/AN/AN/A-1,132.38%-358.54%9/26/2025 (Estimated)

Latest DTIL, ALGS, ESLA, and DYAI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Dyadic International Inc. stock logo
DYAI
Dyadic International
-$0.06-$0.06N/A-$0.06$0.60 million$0.97 million
8/7/2025Q2 2025
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
-$0.09-$2.13-$2.04-$2.13$6.27 million$0.02 million
8/6/2025Q2 2025
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
-$2.35-$1.53+$0.82-$1.53$0.43 million$0.97 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
N/AN/AN/AN/AN/A
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
N/AN/AN/AN/AN/A
Dyadic International Inc. stock logo
DYAI
Dyadic International
N/AN/AN/AN/AN/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
N/A
6.31
6.31
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
0.66
5.18
5.18
Dyadic International Inc. stock logo
DYAI
Dyadic International
5.40
2.02
2.02
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/A
0.16
0.16

Institutional Ownership

CompanyInstitutional Ownership
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
60.43%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
37.99%
Dyadic International Inc. stock logo
DYAI
Dyadic International
27.95%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
0.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
906.15 million5.86 millionNo Data
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
20011.79 million11.26 millionNo Data
Dyadic International Inc. stock logo
DYAI
Dyadic International
736.19 million25.51 millionOptionable
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/A37.07 million16.64 millionNot Optionable

Recent News About These Companies

Estrella Immunopharma (NASDAQ:ESLA) Trading Up 1% - Should You Buy?
ESLA Estrella Immunopharma, Inc.
Estrella Immunopharma completes first dose cohort in STARLIGHT trial

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aligos Therapeutics stock logo

Aligos Therapeutics NASDAQ:ALGS

$11.33 +0.35 (+3.19%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$11.30 -0.03 (-0.26%)
As of 08:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Precision BioSciences stock logo

Precision BioSciences NASDAQ:DTIL

$5.01 -0.03 (-0.60%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$5.02 +0.01 (+0.20%)
As of 08:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Dyadic International stock logo

Dyadic International NASDAQ:DYAI

$0.93 +0.03 (+2.91%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$0.93 0.00 (-0.11%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Estrella Immunopharma stock logo

Estrella Immunopharma NASDAQ:ESLA

$0.94 -0.03 (-3.04%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$0.94 +0.01 (+0.53%)
As of 08/27/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.